Pharming Group Nv Stock EBITDA

PHAR Stock

USD 7.74 0.27 3.61%

Pharming Group NV fundamentals help investors to digest information that contributes to Pharming Group's financial success or failures. It also enables traders to predict the movement of Pharming Stock. The fundamental analysis module provides a way to measure Pharming Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharming Group stock.

		Last Reported	Projected for Next Year
	EBITDA	9.9 M	10.4 M

As of 12/04/2024, EBITDA is likely to grow to about 10.4 M.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pharming Group NV Company EBITDA Analysis

Pharming Group's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Pharming Group EBITDA

9.88 M

Most of Pharming Group's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Pharming EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Pharming Group is extremely important. It helps to project a fair market value of Pharming Stock properly, considering its historical fundamentals such as EBITDA. Since Pharming Group's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pharming Group's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pharming Group's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Good Will	Net Tangible Assets	Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Property Plant Equipment	Capital Stock	Long Term Investments
Total Assets		0.97	0.19	0.38	0.23	0.7	0.88	0.58	0.97	0.99	0.09	0.81	-0.37	-0.28	0.95	0.68	-0.71	0.92	-0.63	0.84	0.87	0.83	0.79
Total Stockholder Equity	0.97		0.19	0.32	0.42	0.59	0.85	0.6	0.88	0.98	-0.04	0.71	-0.28	-0.17	0.98	0.71	-0.73	0.95	-0.67	0.88	0.91	0.85	0.84
Current Deferred Revenue	0.19	0.19		-0.31	-0.14	0.28	0.16	-0.2	0.18	0.11	0.39	0.41	-0.12	-0.12	0.1	-0.19	0.49	0.08	0.23	-0.08	-0.12	0.12	-0.28
Net Debt	0.38	0.32	-0.31		0.07	0.42	0.69	0.89	0.41	0.41	0.05	0.12	-0.12	-0.11	0.41	0.2	-0.46	0.27	-0.27	0.27	0.55	0.49	0.46
Retained Earnings	0.23	0.42	-0.14	0.07		-0.11	0.17	0.3	0.03	0.3	-0.43	-0.02	0.45	0.57	0.38	0.44	-0.39	0.41	-0.45	0.44	0.44	0.33	0.47
Accounts Payable	0.7	0.59	0.28	0.42	-0.11		0.68	0.47	0.77	0.67	0.2	0.72	-0.27	-0.13	0.55	0.47	-0.25	0.58	-0.39	0.54	0.46	0.56	0.4
Net Receivables	0.88	0.85	0.16	0.69	0.17	0.68		0.81	0.86	0.87	0.26	0.66	-0.35	-0.26	0.87	0.41	-0.64	0.74	-0.39	0.64	0.84	0.76	0.71
Short Term Investments	0.58	0.6	-0.2	0.89	0.3	0.47	0.81		0.52	0.65	-0.17	0.15	-0.12	-0.07	0.68	0.43	-0.63	0.54	-0.48	0.53	0.78	0.73	0.67
Total Liab	0.97	0.88	0.18	0.41	0.03	0.77	0.86	0.52		0.94	0.21	0.87	-0.44	-0.36	0.87	0.61	-0.64	0.83	-0.55	0.76	0.77	0.76	0.7
Total Current Assets	0.99	0.98	0.11	0.41	0.3	0.67	0.87	0.65	0.94		-0.05	0.72	-0.35	-0.26	0.97	0.75	-0.76	0.94	-0.72	0.89	0.91	0.88	0.84
Short Term Debt	0.09	-0.04	0.39	0.05	-0.43	0.2	0.26	-0.17	0.21	-0.05		0.47	-0.27	-0.2	-0.07	-0.59	0.22	-0.19	0.67	-0.35	-0.21	-0.3	-0.27
Intangible Assets	0.81	0.71	0.41	0.12	-0.02	0.72	0.66	0.15	0.87	0.72	0.47		-0.39	-0.29	0.65	0.4	-0.35	0.67	-0.29	0.57	0.48	0.44	0.45
Common Stock	-0.37	-0.28	-0.12	-0.12	0.45	-0.27	-0.35	-0.12	-0.44	-0.35	-0.27	-0.39		0.88	-0.28	-0.13	0.2	-0.25	0.11	-0.21	-0.23	-0.21	-0.21
Good Will	-0.28	-0.17	-0.12	-0.11	0.57	-0.13	-0.26	-0.07	-0.36	-0.26	-0.2	-0.29	0.88		-0.22	-0.11	0.15	-0.21	0.09	-0.17	-0.18	-0.16	-0.16
Net Tangible Assets	0.95	0.98	0.1	0.41	0.38	0.55	0.87	0.68	0.87	0.97	-0.07	0.65	-0.28	-0.22		0.71	-0.8	0.95	-0.67	0.89	0.96	0.85	0.89
Long Term Debt	0.68	0.71	-0.19	0.2	0.44	0.47	0.41	0.43	0.61	0.75	-0.59	0.4	-0.13	-0.11	0.71		-0.68	0.85	-0.97	0.94	0.74	0.72	0.8
Deferred Long Term Liab	-0.71	-0.73	0.49	-0.46	-0.39	-0.25	-0.64	-0.63	-0.64	-0.76	0.22	-0.35	0.2	0.15	-0.8	-0.68		-0.77	0.65	-0.79	-0.87	-0.59	-0.93
Net Invested Capital	0.92	0.95	0.08	0.27	0.41	0.58	0.74	0.54	0.83	0.94	-0.19	0.67	-0.25	-0.21	0.95	0.85	-0.77		-0.77	0.97	0.9	0.78	0.91
Short Long Term Debt	-0.63	-0.67	0.23	-0.27	-0.45	-0.39	-0.39	-0.48	-0.55	-0.72	0.67	-0.29	0.11	0.09	-0.67	-0.97	0.65	-0.77		-0.86	-0.73	-0.78	-0.75
Net Working Capital	0.84	0.88	-0.08	0.27	0.44	0.54	0.64	0.53	0.76	0.89	-0.35	0.57	-0.21	-0.17	0.89	0.94	-0.79	0.97	-0.86		0.88	0.75	0.92
Property Plant Equipment	0.87	0.91	-0.12	0.55	0.44	0.46	0.84	0.78	0.77	0.91	-0.21	0.48	-0.23	-0.18	0.96	0.74	-0.87	0.9	-0.73	0.88		0.83	0.96
Capital Stock	0.83	0.85	0.12	0.49	0.33	0.56	0.76	0.73	0.76	0.88	-0.3	0.44	-0.21	-0.16	0.85	0.72	-0.59	0.78	-0.78	0.75	0.83		0.68
Long Term Investments	0.79	0.84	-0.28	0.46	0.47	0.4	0.71	0.67	0.7	0.84	-0.27	0.45	-0.21	-0.16	0.89	0.8	-0.93	0.91	-0.75	0.92	0.96	0.68

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Pharming Group

Ebitda Over Time

Pharming Ebitda

Ebitda

10.37 Million

At this time, Pharming Group's EBITDA is relatively stable compared to the past year.

According to the company disclosure, Pharming Group NV reported earnings before interest,tax, depreciation and amortization of 9.88 M. This is 98.87% lower than that of the Biotechnology sector and 90.14% lower than that of the Health Care industry. The ebitda for all United States stocks is 99.75% higher than that of the company.

Pharming EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharming Group's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics of similar companies.

Pharming Group is currently under evaluation in ebitda category among its peers.

Pharming Group Current Valuation Drivers

We derive many important indicators used in calculating different scores of Pharming Group from analyzing Pharming Group's financial statements. These drivers represent accounts that assess Pharming Group's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pharming Group's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	981.7M	809.3M	497.6M	752.3M	676.7M	710.6M
Enterprise Value	965.6M	766.1M	467.4M	711.7M	786.5M	825.9M

Pharming Group ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pharming Group's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pharming Group's managers, analysts, and investors.

Environmental

Governance

Social

Pharming Group Institutional Holders

Institutional Holdings refers to the ownership stake in Pharming Group that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pharming Group's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pharming Group's value.

		Shares
Silverberg Bernstein Capital Management Llc	2024-09-30	41.1 K
Morgan Stanley - Brokerage Accounts	2024-09-30	3.3 K
Advisor Group Holdings, Inc.	2024-06-30	568
Ubs Group Ag	2024-09-30	0.0

Pharming Fundamentals

	Return On Equity	-0.0818
	Return On Asset	-0.0138
	Profit Margin	(0.06) %
	Operating Margin	0.05 %
	Current Valuation	473.14 M
	Shares Outstanding	67.84 M
	Shares Owned By Institutions	0.10 %
	Number Of Shares Shorted	25.45 K
	Price To Earning	41.53 X
	Price To Book	2.27 X
	Price To Sales	1.81 X
	Revenue	245.32 M
	Gross Profit	188.06 M
	EBITDA	9.88 M
	Net Income	(9.55 M)
	Cash And Equivalents	189.96 M
	Cash Per Share	2.91 X
	Total Debt	171.54 M
	Debt To Equity	0.75 %
	Current Ratio	5.22 X
	Book Value Per Share	0.44 X
	Cash Flow From Operations	(17.3 M)
	Short Ratio	4.22 X
	Earnings Per Share	(0.27) X
	Target Price	33.5
	Number Of Employees	382
	Beta	0.81
	Market Capitalization	518.15 M
	Total Asset	462.85 M
	Retained Earnings	(265.26 M)
	Working Capital	238.37 M
	Net Asset	462.85 M

About Pharming Group Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC